Complete Listing of the Claims

This Listing of Claims replaces all prior versions of claims in the Subject Application.

 (Currently amended) A method of expanding a population of human hematopoietic stem cells by promoting self-renewal of the population of human hematopoietic stem cells comprising:

delivering small RNA interfering sequences (siRNA) to the human <u>hematopoietic</u> stem cells for the reduction of p18 levels in the intracellular environment of the stem cells.

- (Currently amended) The method of claim 1, wherein said human <u>hematopoietic</u> stem cells are adult stem CD34+ cells.
- 3-5. (Canceled)
- (Currently amended) The method of claim 1 further comprising implanting the siRNA treated human hematopoietic stem cells into a human.
- (Currently amended) The method of claim 6, wherein said siRNA treated human hematopoietic stem cells are adult-stem CD34+ cells.
- 8-22. (Canceled)
- 23. (Currently amended) A method of stimulating self-renewal of a population of human hematopoietic stem cells by reducing intracellular levels of p18 comprising: delivering small RNA interfering sequences (siRNA) to the human hematopoietic stem cells by one of electroporation or lentiviral vector for the reduction of p18 levels in the intracellular environment of the stem cells.

- 24. (Currently amended) The method of claim 23, wherein said human hematopoietic stem cells are adult stem CD34+ cells.
- 25. (Canceled)
- 26. (Currently amended) The method of claim 23, further comprising implanting the siRNA treated human hematopoietic stem cells into a human.
- 27. (Currently amended) The method of claim 26, wherein said siRNA treated human hematopoietic stem cells are adult stem CD34+ cells.
- 28-32. (Canceled)
- 33. (Currently amended) The method of claim 6, wherein the siRNA treated human hematopoietic stem cells contain no intracellular p18.
- 34-37 (Canceled)
- 38. (Currently amended) The method of claim 26, wherein the siRNA treated human <u>hematopoietic</u> stem cells contain no intracellular p18.
- 39. (Currently amended) The A method of promoting self-renewal of a population of human hematopoietic stem cells comprising:

expanding the population of human <u>hematopoietic</u> stem cells by delivering small RNA interfering sequences (siRNA) to the human <u>hematopoietic</u> stem cells for a reduction of p18 levels in the intracellular environment of the stem cells.

 (New) The method of claim 1, wherein the siRNA treated human hematopoietic stem cells contain no intracellular p18.

- 41. (New) The method of claim 23, wherein the siRNA treated human hematopoietic stem cells contain no intracellular p18.
- 42. (New) The method of claim 39, wherein said human hematopoietic stem cells are CD34+ cells.
- 43. (New) The method of claim 39, wherein the siRNA treated human hematopoietic stem cells contain no intracellular p18.